Datasea Announces Major Acoustic Technology Advancements in Brain-Computer Interface Applications

Rhea-AI Summary

Datasea (NASDAQ: DTSS) announced progress on two acoustic-driven brain–computer interface (BCI) initiatives on Jan 12, 2026, targeting assistive communication for neurological patients and upper-limb rehabilitation robot control. The work advances acoustic-enabled BCI from signal acquisition toward system-level integration by combining acoustic signal enhancement, EEG feature selection, flexible MXene electrodes, and transcranial closed-loop ultrasound modulation.

The company said it has begun collaborations with domestic health robotics firms, including Nanjing Linghang, to validate integration and explore commercialization amid a projected global BCI market of USD 15–20 billion by 2030.

News Market Reaction – DTSS

+4.34%

1 alert

+4.34% News Effect

+$328K Valuation Impact

$8M Market Cap

0.0x Rel. Volume

On the day this news was published, DTSS gained 4.34%, reflecting a moderate positive market reaction. This price movement added approximately $328K to the company's valuation, bringing the market cap to $8M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Global BCI market size: USD 15–20 billion BCI timeline: 2030

2 metrics

Global BCI market size USD 15–20 billion Projected by 2030 per 2024 industry reports cited in article

BCI timeline 2030 Projection year for global brain–computer interface market size

Market Reality Check

Price: $0.9130 Vol: Volume 8,466 is far below...

low vol

$0.9130 Last Close

Volume Volume 8,466 is far below the 20-day average of 107,768 (relative volume 0.08). low

Technical Shares at 0.8047 trade 74.04% below the 52-week high and 25.73% above the 52-week low, remaining below the 200-day MA of 1.86.

Peers on Argus

DTSS was down 3.05% with most peers also weaker: BNAI -7.25%, FAAS -8.3%, OLB -2...

DTSS was down 3.05% with most peers also weaker: BNAI -7.25%, FAAS -8.3%, OLB -2.28%, MSAI -0.56%, while BLIN gained 0.41%. This suggests pressure across similar small-cap software/AI names despite the positive BCI technology update.

Historical Context

5 past events · Latest: Jan 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	BCI collaboration	Positive	+21.3%	Strategic collaboration to apply acoustic BCI tech to healthcare robots.
Dec 17	Commercial partnership	Positive	-3.1%	Nationwide Beauty & Health system rollout with specified fee structures.
Dec 11	BCI technology milestone	Positive	+14.6%	Completion of acoustic-driven BCI systems for signal enhancement and feedback.
Nov 18	Operations update	Positive	+14.5%	Statement on normal operations and gross profit improvement amid trading volatility.
Nov 13	Earnings update	Neutral	-4.0%	Revenue decline but sharp gross profit and margin improvement during strategic pivot.

Pattern Detected

Recent BCI- and tech-focused announcements have often coincided with positive price reactions, while at least one commercial partnership drew a negative response, indicating selective investor enthusiasm for Datasea’s news flow.

Recent Company History

Over the last few months, Datasea has highlighted a clear pivot toward acoustic-driven AI and brain–computer interface technologies. On Nov 13, 2025, it reported Q1 revenue of $13.81M with gross margin rising to 8.46%. Subsequent releases on Nov 18 and Dec 11, 2025 emphasized going‑concern risks but also major BCI engineering milestones, both met with double-digit stock gains. A Jan 5, 2026 collaboration around non-invasive BCI and healthcare robots also produced a strong positive reaction, consistent with market focus on BCI progress.

Market Pulse Summary

This announcement details further integration of Datasea’s acoustic-driven brain–computer interface ...

Analysis

This announcement details further integration of Datasea’s acoustic-driven brain–computer interface platform, extending from EEG signal enhancement into assistive communication and rehabilitation robotics control. It builds on prior late‑2025 BCI milestones and a Jan 5, 2026 collaboration focused on healthcare robots. Investors may track progress on system‑level validation, partnerships like those with domestic health robotics firms, and any future financial disclosures that link these R&D advances to revenue and margin trends.

Key Terms

brain–computer interface, electroencephalogram (EEG), genetic algorithms, fourier transform, +4 more

8 terms

brain–computer interface medical

"two acoustic-driven technology initiatives related to brain–computer interfaces ("BCI") and rehabilitation"

A brain–computer interface is a technology that reads signals from a person’s brain and translates them into commands a computer or machine can understand, allowing direct control without physical movement. For investors, it matters because successful BCI products can create new markets in healthcare, assistive devices, and consumer electronics, similar to how touchscreens opened whole industries; they carry high potential returns but also technical, regulatory, and ethical risks that affect company value.

electroencephalogram (EEG) medical

"those technologies enhanced the quality and usability of raw electroencephalogram (EEG) signals"

A noninvasive test that records the brain’s electrical activity using small sensors placed on the scalp, producing waveform patterns that reflect how brain cells are firing—think of it as a seismograph for electrical signals in the brain. Investors care because EEGs are widely used to diagnose and monitor neurological conditions, evaluate drug or device effects in clinical trials, and support regulatory and commercial decisions; changes in EEG results can influence trial outcomes, approvals, and market prospects.

genetic algorithms technical

"Intent Interpretation：Genetic algorithms are used for EEG feature selection, combined with Fourier"

Computer methods that mimic natural evolution to find good solutions to complex problems: they create many candidate solutions, keep the best, mix and randomly change them, and repeat the process until a strong solution emerges. Investors care because genetic algorithms can help tune trading rules, build portfolios, or optimize models when there are too many possible choices for traditional methods to search; they can speed discovery but may also produce fragile or over-tailored results if not used carefully.

fourier transform technical

"Genetic algorithms are used for EEG feature selection, combined with Fourier and Hilbert–Huang transforms"

A Fourier transform is a mathematical tool that breaks a changing signal, like a price chart over time, into basic repeating components—much like identifying individual notes in a musical chord. For investors, it helps reveal hidden cycles and recurring patterns, filter out random noise, and improve technical analysis or algorithmic models, so decisions can be based on clearer, more predictable parts of noisy market data.

hilbert–huang transforms technical

"feature selection, combined with Fourier and Hilbert–Huang transforms to extract multidimensional"

A Hilbert–Huang transform is a two-step signal analysis method that breaks a messy, changing time series into simple oscillating components and then measures how each component’s frequency and strength evolve over time. For investors, it helps reveal shifting cycles, short-term trends, and bursts of volatility in price or volume data—think of isolating separate instruments in a noisy song so you can hear changing rhythms that may signal opportunities or risks.

mxene technical

"exploring flexible MXene electrode membranes incorporating crosslinked β-cyclodextrin to balance"

Mxenes are a family of extremely thin, sheet-like materials made from layers of metal combined with carbon or nitrogen, similar in feel to graphene but with metallic conductivity and flexible chemistry. They matter to investors because their unique electrical, thermal and surface properties could improve batteries, sensors, coatings and electronic components, potentially lowering costs or enabling new products—think of them as tunable, high-performance metal “sheets” that companies can fold into many commercially valuable uses.

β-cyclodextrin medical

"flexible MXene electrode membranes incorporating crosslinked β-cyclodextrin to balance biocompatibility"

β-cyclodextrin is a ring-shaped sugar molecule used as a formulation ingredient to trap, protect or dissolve other chemicals; think of it as a tiny donut that can hold a marble to make the marble easier to carry. It matters to investors because it can improve a drug’s stability, solubility, taste or shelf life, affect manufacturing costs, influence regulatory review, and enable new product formulations that can change a product’s marketability and value.

transcranial closed-loop ultrasound modulation medical

"Closed-Loop System：Transcranial closed-loop ultrasound modulation is integrated into signal"

A noninvasive technique that uses focused sound waves sent through the skull to influence brain activity while continuously monitoring responses and adjusting the stimulation in real time, like a thermostat that changes heat based on room temperature. Investors care because it aims to treat neurological conditions without surgery, so success affects clinical trial results, device approvals, safety profiles and potential market size for medical devices and therapies.

AI-generated analysis. Not financial advice.

Acoustic-Driven Technologies Poised to Support Embodied Intelligence and Health Robotics Applications in a Multi-Billion-Dollar Brain–Computer Interface Market

BEIJING, Jan. 12, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in acoustic high-tech innovation and AI-powered multimodal systems, today announced that its China-based operating entities and subsidiaries have recently made progress in two acoustic-driven technology initiatives related to brain–computer interfaces ("BCI") and rehabilitation robot control, leveraging proprietary acoustic-driven technologies.

The Company stated that these advancements represent an important extension of its acoustic-driven BCI core technology framework previously disclosed in late 2025. The new developments further advance acoustic-enabled BCI technologies from foundational neural signal processing toward engineering-level system integration and practical applications in embodied intelligence scenarios, including medical rehabilitation and health robotics.

Two Acoustic Technology Advancements: Progress Toward System-Level BCI Applications

The two newly developed acoustic technology initiatives focus on two application directions within brain–computer interface research: assistive communication and rehabilitation robot control. These initiatives form part of the Company's ongoing efforts to explore how acoustic-driven approaches may support the translation of neural signals into system-level control mechanisms under practical application scenarios.

BCI-Based Communication and Care Assistance System

One initiative is oriented toward assistive communication and care scenarios for patients with neurological conditions, such as stroke survivors. The technology is being developed to explore a brain–computer interface–based intention recognition and system control framework, with the objective of interpreting neural signals and mapping user intent into control instructions for external devices or systems.

The Company believes this approach may help address certain practical challenges commonly observed in applied BCI research, including variability in neural signal quality, limitations in coordinating neural outputs with device-level control systems, and the need for more stable interaction mechanisms in assisted communication and caregiving environments. Through a system-oriented design approach, this initiative is intended to support further exploration of intent-driven human–machine interaction models applicable to assistive care contexts.

BCI-Based Upper-Limb Rehabilitation Robot Control System

The second initiative focuses on rehabilitation robotics and explores a system-level method for translating neural signals acquired through brain–computer interfaces into structured control logic suitable for upper-limb rehabilitation training robots. This effort is aimed at examining how neural signal interpretation may be more effectively aligned with robotic execution processes in rehabilitation settings.

By integrating neural signal decoding, control logic generation, and robotic execution within a unified system framework, the Company is seeking to establish a technical reference model for the future development of intent-driven rehabilitation training systems and human–machine collaboration approaches, while continuing to evaluate adaptability across different users and rehabilitation scenarios.

Synergy with Datasea's Acoustic-Driven Brain–Computer Interface Technology Framework

Integration Within Datasea's Acoustic-Driven BCI Technology Framework

Datasea's R&D team noted that the Company's previously disclosed technologies related to acoustic coupling and neuromodulation primarily addressed noise interference, signal attenuation, and stability issues during BCI signal acquisition and transmission. By leveraging acoustic and ultrasonic techniques, those technologies enhanced the quality and usability of raw electroencephalogram (EEG) signals, providing more reliable inputs for downstream processing.

Building on this foundation, the newly announced advancements further deepen and integrate the core BCI technology chain across multiple layers:

• Signal Enhancement: An acoustic-driven signal enhancement approach based on NeRF acoustic field modeling and nested generative networks supplements missing or incomplete EEG data through acoustic coupling mechanisms, while introducing physical–physiological consistency constraints to improve signal integrity and stability.
• Intent Interpretation：Genetic algorithms are used for EEG feature selection, combined with Fourier and Hilbert–Huang transforms to extract multidimensional time–frequency features, enabling the construction of personalized user models that address inter-individual neural signal variability.
• Hardware Adaptation: The Company is exploring flexible MXene electrode membranes incorporating crosslinked β-cyclodextrin to balance biocompatibility and anti-swelling properties, enabling relatively stable inductive characteristics in fluid environments and supporting non-invasive BCI signal acquisition.
• Closed-Loop System：Transcranial closed-loop ultrasound modulation is integrated into signal processing and interaction workflows to form a closed-loop structure encompassing ultrasound stimulation, neural signal acquisition, real-time feedback, and device execution.

Datasea believes that the coordinated evolution of algorithms, models, materials, and system architecture forms a complete technical loop—from acoustic-driven signal enhancement to personalized intent decoding, structured system control, and physical execution feedback—laying an industrial-grade foundation for the engineering deployment of BCI technologies in embodied intelligence systems, particularly health robots and rehabilitation devices.

Based on this framework, the Company has initiated collaborations with domestic health robotics companies, including Nanjing Linghang, to integrate acoustic-driven BCI technologies into health robot system architectures for system-level validation and application exploration, advancing the transition from R&D to practical deployment and commercialization.

Market Background

According to industry reports released in 2024 by Grand View Research and Fortune Business Insights, the global brain–computer interface market is experiencing sustained development:

• Global BCI market size is projected to reach approximately USD 15–20 billion by 2030;
• Non-invasive BCI technologies are expected to be among the fastest-growing segments due to safety, accessibility, and broader application potential;
• Medical rehabilitation, consumer electronics, and intelligent wearable devices are anticipated to be key demand drivers over the next decade.

The Company believes that continued growth in rehabilitation medicine and eldercare demand, together with a maturing technology and application ecosystem, will provide a favorable environment for long-term R&D, engineering validation, and application expansion of BCI-related technologies.

CEO Commentary

Ms. Zhixin Liu, Chief Executive Officer of Datasea, stated:

"These two BCI-related acoustic technology advancements represent another important milestone in the continued evolution of our acoustic-driven technology platform. Building on our prior progress in addressing neural signal transmission stability, the new developments in personalized decoding, flexible hardware, and closed-loop modulation further enable the interpretation and understanding of neural signals and their transformation into executable, structured control commands. This allows our technologies to be practically deployed in embodied intelligence systems, including health robotics.

These advancements not only reinforce our core technology barriers, but also further clarify our long-term strategy centered on 'acoustic technology plus multi-scenario applications.' Our expanding patent portfolio in acoustics and brain–computer interfaces strengthens our positioning in acoustic intelligence, BCI, and embodied intelligence convergence, and supports multi-layer collaboration with intelligent hardware companies, including health robotics manufacturers.

We are advancing brain–computer interface technologies from the laboratory into real-world applications, with the goal of delivering tangible benefits to neurological rehabilitation patients and health management users. We are confident in our ability to gradually build competitive advantages in these specialized markets and to create sustainable long-term value for our shareholders."

About Datasea Inc.

Datasea Inc. ("Datasea") is a leading provider of products, services, and solutions for enterprise and retail customers in two innovative industries, acoustic high tech and 5G-AI multimodal digitalization. The Company's advanced R&D technology serves as the core infrastructure and backbone for its products. Its 5G multimodal digital segment operates on a cloud platform based on AI. Datasea leverages cutting-edge technologies, precision manufacturing, and ultrasonic, infrasound and directional sound technology in its acoustics business to combat viruses and prevent human infections, and it is also developing applications in medical ultrasonic cosmetology. In July 2023, Datasea established a wholly-owned subsidiary, Datasea Acoustics LLC, in Delaware, in a strategic move to enter the U.S. markets and to mark its global expansion plan. For additional information, please visit www.dataseainc.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea's control, which may cause Datasea's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea's filings with the SEC, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact: 

Datasea Investor Relations
Email:  investorrelations@shuhaixinxi.com
            sunhezhi@shuhaixinxi.com 

Precept Investor Relations LLC
David Rudnick
+1 646-694-8538
david.rudnick@preceptir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/datasea-announces-major-acoustic-technology-advancements-in-braincomputer-interface-applications-302658370.html

SOURCE Datasea Inc.

FAQ

What BCI applications did Datasea (DTSS) announce on January 12, 2026?

Datasea announced two acoustic-driven BCI initiatives: an assistive communication and care system and an upper-limb rehabilitation robot control system.

How does Datasea (DTSS) improve EEG signals for its acoustic-driven BCI work?

The company described acoustic-driven signal enhancement using NeRF acoustic field modeling and nested generative networks to supplement incomplete EEG data and improve stability.

Which companies is Datasea (DTSS) collaborating with to validate its BCI technologies?

Datasea said it has initiated collaborations with domestic health robotics companies, including Nanjing Linghang, for system-level validation and integration.

What hardware advances did Datasea (DTSS) report for non-invasive BCI acquisition?

Datasea is exploring flexible MXene electrode membranes with crosslinked β-cyclodextrin to balance biocompatibility and anti-swelling for stable non-invasive signal acquisition.

Does Datasea (DTSS) describe closed-loop capability in its BCI systems?

Yes. The company described integrating transcranial closed-loop ultrasound modulation with signal acquisition, real-time feedback, and device execution to form a closed-loop system.

What market opportunity did Datasea (DTSS) cite for its BCI technologies?

Datasea referenced industry reports projecting a global BCI market of approximately USD 15–20 billion by 2030, noting demand drivers like medical rehabilitation and wearable devices.